Stock Track | Sage Therapeutics Plunges as Q3 Earnings Disappoint Despite Zurzuvae Growth

Stock Track

2024/10/30

Shares of Sage Therapeutics Inc. (SAGE) plummeted by 9.32% in premarket trading on Tuesday, October 30th, as the biopharmaceutical company reported mixed third-quarter results and faced setbacks in its pipeline.

While Sage's lead product, Zurzuvae, continued to gain traction in the postpartum depression (PPD) market, generating $22.1 million in total revenue for the quarter (up 49% from Q2), the company's overall financial performance and updates on other programs failed to impress investors.

Sage reported a net loss of $93.6 million for the third quarter, missing analyst estimates on revenue and earnings per share. The company also faced several pipeline setbacks, including the discontinuation of commercial availability for its drug Zulresso, a Phase 2 trial failure for an Alzheimer's disease candidate, and the termination of a collaboration with Biogen on the SAGE-324 program.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1179660506"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179660506\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179660506?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179660506","market":"us","top_or_hot":-1,"title":"Stock Track | Sage Therapeutics Plunges as Q3 Earnings Disappoint Despite Zurzuvae Growth","media":"Stock Track","content":"<p>Shares of Sage Therapeutics Inc. (SAGE) plummeted by 9.32% in premarket trading on Tuesday, October 30th, as the biopharmaceutical company reported mixed third-quarter results and faced setbacks in its pipeline.</p>\n\n<p>While Sage's lead product, Zurzuvae, continued to gain traction in the postpartum depression (PPD) market, generating $22.1 million in total revenue for the quarter (up 49% from Q2), the company's overall financial performance and updates on other programs failed to impress investors.</p>\n\n<p>Sage reported a net loss of $93.6 million for the third quarter, missing analyst estimates on revenue and earnings per share. The company also faced several pipeline setbacks, including the discontinuation of commercial availability for its drug Zulresso, a Phase 2 trial failure for an Alzheimer's disease candidate, and the termination of a collaboration with Biogen on the SAGE-324 program.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Sage Therapeutics Plunges as Q3 Earnings Disappoint Despite Zurzuvae Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Sage Therapeutics Plunges as Q3 Earnings Disappoint Despite Zurzuvae Growth\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-10-30 21:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Sage Therapeutics Inc. (SAGE) plummeted by 9.32% in premarket trading on Tuesday, October 30th, as the biopharmaceutical company reported mixed third-quarter results and faced setbacks in its pipeline.</p>\n\n<p>While Sage's lead product, Zurzuvae, continued to gain traction in the postpartum depression (PPD) market, generating $22.1 million in total revenue for the quarter (up 49% from Q2), the company's overall financial performance and updates on other programs failed to impress investors.</p>\n\n<p>Sage reported a net loss of $93.6 million for the third quarter, missing analyst estimates on revenue and earnings per share. The company also faced several pipeline setbacks, including the discontinuation of commercial availability for its drug Zulresso, a Phase 2 trial failure for an Alzheimer's disease candidate, and the termination of a collaboration with Biogen on the SAGE-324 program.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SAGE","symbol_name":"Sage Therapeutics","start_time":0,"source_url":"","article_id":"1179660506","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179660506","pubTimestamp":1730295327,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Sage Therapeutics Inc.  plummeted by 9.32% in premarket trading on Tuesday, October 30th, as the biopharmaceutical company reported mixed third-quarter results and faced setbacks in its pipeline.While Sage's lead product, Zurzuvae, continued to gain traction in the postpartum depression  market, generating $22.1 million in total revenue for the quarter , the company's overall financial performance and updates on other programs failed to impress investors.Sage reported a net loss of $93","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SAGE":"Sage Therapeutics"},"translate_title":"尽管Zurzuvae增长，但第三季度盈利令人失望，Sage Therapeutics股价暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAGE":1},"content_text":"Shares of Sage Therapeutics Inc. (SAGE) plummeted by 9.32% in premarket trading on Tuesday, October 30th, as the biopharmaceutical company reported mixed third-quarter results and faced setbacks in its pipeline.\nWhile Sage's lead product, Zurzuvae, continued to gain traction in the postpartum depression (PPD) market, generating $22.1 million in total revenue for the quarter (up 49% from Q2), the company's overall financial performance and updates on other programs failed to impress investors.\nSage reported a net loss of $93.6 million for the third quarter, missing analyst estimates on revenue and earnings per share. The company also faced several pipeline setbacks, including the discontinuation of commercial availability for its drug Zulresso, a Phase 2 trial failure for an Alzheimer's disease candidate, and the termination of a collaboration with Biogen on the SAGE-324 program.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}